Immatics reports positive Phase II for colorectal cancer vaccine
This article was originally published in Scrip
Executive Summary
Tuebingen, Germany-based Immatics biotechnologies has reported positive Phase II results for its therapeutic cancer vaccine, IMA910, in patients with advanced colorectal cancer (CRC), which the company claims "show a clear association between the patient's ability to mount an immune response to the tumour associated peptides (TUMAPs) in IMA910 and overall survival".